Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries
Sponsor: Stanford University
Summary
The goal of this clinical trial is to learn if targeted medical therapy will improve symptoms and quality of life in patients with angina and non-obstructive coronary arteries compared to placebo, after the underlying cause of the chest pain has been ascertained by coronary function testing. Participants will be treated with either medications that target the underlying cause of their chest pain or placebo for 4 weeks after a drug titration phase of 1-3 weeks. They will be asked to complete a series of questionnaires to evaluate their quality of life at the beginning and end of the study.
Official title: A Randomized Controlled Study of Targeted Medical Therapy Versus Placebo for Angina and Non- Obstructive Coronary Arteries: The MVP-ANOCA Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2024-10-10
Completion Date
2026-12
Last Updated
2024-11-27
Healthy Volunteers
No
Interventions
Amlodipine
Amlodipine taken once orally daily at a starting dose of 2.5mg, uptitrated to a maximum of 10mg if tolerated.
Nebivolol
Nebivolol taken once orally daily at a starting dose of 5mg, uptitrated to a maximum of 20mg if tolerated.
Placebo
Placebo taken once orally daily.
Locations (1)
Stanford Hospital
Palo Alto, California, United States